| Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia DA Pollyea, BM Stevens, CL Jones, A Winters, S Pei, M Minhajuddin, ... Nature medicine 24 (12), 1859-1866, 2018 | 781 | 2018 |
| Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia S Pei, DA Pollyea, A Gustafson, BM Stevens, M Minhajuddin, R Fu, ... Cancer discovery 10 (4), 536-551, 2020 | 538 | 2020 |
| MLL-rearranged leukemias—an update on science and clinical approaches AC Winters, KM Bernt Frontiers in pediatrics 5, 4, 2017 | 512 | 2017 |
| Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells BM Stevens, CL Jones, DA Pollyea, R Culp-Hill, A D’Alessandro, ... Nature cancer 1 (12), 1176-1187, 2020 | 316 | 2020 |
| Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells CL Jones, BM Stevens, DA Pollyea, R Culp-Hill, JA Reisz, T Nemkov, ... Cell stem cell 27 (5), 748-764. e4, 2020 | 240 | 2020 |
| Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia EM Cherry, D Abbott, M Amaya, C McMahon, M Schwartz, J Rosser, ... Blood advances 5 (24), 5565-5573, 2021 | 192 | 2021 |
| Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia AC Winters, JA Gutman, E Purev, M Nakic, J Tobin, S Chase, J Kaiser, ... Blood advances 3 (20), 2911-2919, 2019 | 162 | 2019 |
| Subversion of systemic glucose metabolism as a mechanism to support the growth of leukemia cells H Ye, B Adane, N Khan, E Alexeev, N Nusbacher, M Minhajuddin, ... Cancer cell 34 (4), 659-673. e6, 2018 | 140 | 2018 |
| The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation ML Amaya, A Inguva, S Pei, C Jones, A Krug, H Ye, M Minhajuddin, ... Blood, The Journal of the American Society of Hematology 139 (4), 584-596, 2022 | 135 | 2022 |
| A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy S Pei, IT Shelton, AE Gillen, BM Stevens, M Gasparetto, Y Wang, L Liu, ... Cancer Discovery, CD-22-1297, 2023 | 99 | 2023 |
| Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML … DA Pollyea, A Winters, C McMahon, M Schwartz, CT Jordan, ... Bone Marrow Transplantation 57 (2), 160-166, 2022 | 94 | 2022 |
| Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes BM Stevens, N Khan, A D’Alessandro, T Nemkov, A Winters, CL Jones, ... Nature Communications 9 (1), 3694, 2018 | 94 | 2018 |
| Single‐center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia AC Winters, KW Maloney, AL Treece, L Gore, AK Franklin Pediatric Blood & Cancer 67 (10), e28398, 2020 | 70 | 2020 |
| Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax+ Azacitidine Versus … AC Winters, G Bosma, D Abbott, M Minhajuddin, C Jordan, DA Pollyea, ... Transplantation and Cellular Therapy 28 (10), 694. e1-694. e9, 2022 | 51 | 2022 |
| CD123 CAR T cells for the treatment of myelodysplastic syndrome BM Stevens, W Zhang, DA Pollyea, A Winters, J Gutman, C Smith, ... Experimental hematology 74, 52-63. e3, 2019 | 49 | 2019 |
| The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells CM Palermo, CA Bennett, AC Winters, CS Hemenway Leukemia research 32 (4), 633-642, 2008 | 43 | 2008 |
| Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse A Kent, M Schwartz, C McMahon, M Amaya, CA Smith, J Tobin, ... Bone Marrow Transplantation, 1-6, 2023 | 39 | 2023 |
| Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium AI Sheth, MJ Althoff, H Tolison, K Engel, ML Amaya, AE Krug, TN Young, ... Cancer Discovery, 2024 | 31 | 2024 |
| Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse A Kent, DA Pollyea, A Winters, CT Jordan, C Smith, JA Gutman Blood 136, 11-12, 2020 | 29 | 2020 |
| PTPN11 mutations confer unique metabolic properties and increase resistance to venetoclax and azacitidine in acute myelogenous leukemia BM Stevens, CL Jones, A Winters, J Dugan, D Abbott, MR Savona, ... Blood 132, 909, 2018 | 27 | 2018 |
